The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PHVS | +26.92% | N/A | N/A | -2% |
| S&P | +14.18% | +88.25% | +13.47% | +76% |
Pharvaris NV operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for rare diseases focused on angioedema and other bradykinin-mediated diseases. Its PHA121 program is designed to treat all sub-types of hereditary angioedema. The company was founded by Luc Dochez, Jens Schneider-Mergener, Berndt A. E. Modig, Jochen Knolle, Hans Gerardus Christiaan Petrus Schikan, and Anne Lesage on September 30, 2015 and is headquartered in Leiden, the Netherlands.
Bain Capital sold $20 million worth of Pharvaris stock during the third quarter.
Promising news from the Food and Drug Administration spurred the healthcare stock's rise.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.12M | -156.7% |
| Market Cap | $1.60B | 59.8% |
| Market Cap / Employee | $14.02M | 0.0% |
| Employees | 114 | 37.3% |
| Net Income | -$43.40M | 5.3% |
| EBITDA | -$46.23M | -11.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $386.91M | 13.6% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.52M | 2553.3% |
| Short Term Debt | $0.16M | 45.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -48.37% | 5.9% |
| Return On Invested Capital | -35.03% | -1.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$38.21M | -0.5% |
| Operating Free Cash Flow | -$38.18M | -1.3% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.14 | 2.57 | 3.94 | 6.31 | 125.05% |
| Price to Tangible Book Value | 3.14 | 2.57 | 3.45 | 6.31 | 125.05% |
| Enterprise Value to EBITDA | -18.07 | -12.52 | -15.96 | -25.25 | 41.11% |
| Return on Equity | -41.4% | -51.9% | -64.0% | -51.8% | -10.91% |
| Total Debt | $0.89M | $0.80M | $0.74M | $0.68M | 420.97% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
